Statement of Principles concerning hypogonadism (Reasonable Hypothesis) (No. 73 of 2021)

The Statement operates around a tight set of legal/medical concepts that are explicit in the instrument. Understanding these concepts is essential for how decision‑makers and claimants use the instrument in the VEA/MRCA claims process.

Hypogonadism: The instrument defines hypogonadism as deficient production of testosterone from testes or oestrogen from ovaries, or deficient production of ova or sperm where such deficiency is associated with clinical symptoms or a requirement for treatment (s 6(2)(a)). It expressly includes both primary and secondary forms and endocrine/gonadal infertility (s 6(2)(b)(i)-(iii)), and excludes several conditions that may be clinically adjacent, such as naturally occurring menopause and abnormal semen analysis (s 6(2)(c)). The instrument also links hypogonadism to death where death involved a terminal event contributed to by hypogonadism (s 6(3)).

Reasonable hypothesis threshold and factors: The statutory framing is a “reasonable hypothesis” standard, not proof on the balance of probabilities. Section 8 establishes that at least one enumerated factor must exist before a reasonable hypothesis can be said to be raised connecting hypogonadism (or death from hypogonadism) to the circumstances of relevant service. The factors are detailed and often binary or thresholded. Examples include endocrine diagnoses at the time of clinical onset (e.g. hypopituitarism with FSH/LH deficiency (s 8(1)); hyperprolactinaemia (s 8(2)); mumps orchitis affecting both testes or a single functional testis (s 8(10)); and exposure thresholds such as cumulative inhalation of metal fumes for at least 2,000 hours (s 8(28)).

Temporal and causal distinctions: The Statement differentiates between factors that relate to clinical onset and those that relate to “clinical worsening” of hypogonadism. Subsections in section 8 are grouped so that 8(1)-(38) cover factors required for a reasonable hypothesis about causation (onset), while 8(39)-(77) parallel many of those factors for the situation where the issue is material contribution to, or aggravation of, pre‑existing hypogonadism (s 8; s 9(2)). Section 9(2) clarifies that subsections 8(39)-(77) apply only to material contribution to or aggravation where the hypogonadism was suffered or contracted before or during (but did not arise out of) relevant service.

Defined thresholds and measurable criteria: Many concepts are given numeric or operational definitions in Schedule 1. BMI thresholds define “being obese” (BMI 30 or greater) and “being underweight” (BMI 18.5 or less) and define BMI itself (Schedule 1, Dictionary). Smoking is quantified by pack‑years with a specific conversion for non‑cigarette tobacco (one pack‑year defined in Schedule 1). Exposure durations for inhaled fumes, chemicals and TCDD contamination are specified (e.g. 2,000 cumulative hours for certain chemical/metal exposures, 1,000 hours within a 10‑year window for TCDD contamination for females, with onset windows after cessation; s 8(28)-(30)). Specific drug lists (Specified List 1 and Specified List 2) are enumerated in the Schedule with named agents, sometimes sex‑specific (Schedule 1).

Cross‑reference to other Statements of Principles: Section 10 provides that if a factor in this Statement refers to an injury or disease covered by another Statement of Principles determined under subsection 196B(2) of the VEA, the factors in that other Statement apply in accordance with that Statement as in force from time to time. This creates an integration mechanism for overlapping medical conditions.

Authority and evidentiary character: The RMA records its view that there is sound medical‑scientific evidence supporting relationships between hypogonadism and relevant service (s 7). The instrument is an RMA product under the VEA regime. It is presented as a determinative scientific standard for application in statutory decision making, but it is not itself a grant of compensation or a facts adjudicator; the Statement supplies the medical criteria decision‑makers must consider when evaluating whether a reasonable hypothesis of service connection exists (s 3-4, s 7).

The instrument’s immediate legal audience is claimants and decision‑makers operating in the VEA and MRCA claim systems. The Statement applies to claims to which section 120A of the VEA or section 338 of the MRCA apply (s 4). Those statutory provisions govern service‑related claims and recourse within those Acts. Practically, affected parties include veterans, members of the Forces, members of Peacekeeping Forces and the administrative bodies and medical assessors who determine entitlement under those Acts.

Veterans and serving members: Any person lodging a claim under section 120A of the VEA or section 338 of the MRCA for hypogonadism or death from hypogonadism will have this Statement applied to the medical causation threshold for a “reasonable hypothesis” (s 4, s 6). The Statement frames which medical or exposure factors, if established, can support a finding that the condition is connected to relevant service (s 8). Specific sex‑based provisions mean the Statement affects men and women differently in practice: certain factors are limited to males only (for example spinal cord injury resulting in paraplegia or tetraplegia, testicular varicocoele, obstructive sleep apnoea in males; see s 8(3), (14), (38), (52), (76)) and others to females only (for example TCDD contamination exposure rules, smoking pack‑year thresholds, nulliparity, inability to breast feed; see s 8(30), (31), (33)-(36), (68)-(69), (72)-(74)).

Medical practitioners and assessors: Endocrinologists, treating physicians, and independent medical examiners will be affected in that their clinical records, diagnostic tests and opinions become the primary evidence used to establish the factors listed. Many factors require laboratory or imaging evidence (for example FSH/LH deficiency, hyperprolactinaemia, chronic kidney disease markers, infarction of ovaries/testes, stem cell transplant records, radiation fields) or documented treatment timelines (e.g. drug duration, radiation field involvement, dates of surgery) (s 8; Schedule 1). Clinicians will need to map clinical findings and records to the specific phrases used in the Statement, such as “clinical onset” and “clinical worsening”.

Administrators and legal advisers: Decision‑makers in the Department and the Repatriation Commission, legal advisers, advocates and tribunal practitioners must align evidentiary strategies to the Statement’s thresholds. For example, establishing a cumulative exposure of 2,000 hours to specified metal fumes or chemicals requires employment records or affidavits that prove such exposure (s 8(28)-(29)). The Schedule provides precise conversions and definitions that will influence evidentiary collection and argument (Schedule 1).

Secondary stakeholders: Employers, industrial hygienists, and records custodians may be asked for workplace exposure records, task rosters, equipment maintenance logs, or incident reports to substantiate cumulative exposure thresholds. Where smoking history, BMI history, or breastfeeding history is material, primary care records and obstetric histories become relevant evidence. Where a factor refers to an injury or disease covered by another Statement of Principles, that other Statement’s factors will apply (s 10), so stakeholders involved in the overlapping conditions are also implicated.

Who does not have new obligations in legislation: The instrument does not itself impose criminal penalties or civil liabilities on third parties. It does not create entitlements or payments directly. Its regulatory effect is procedural and evidentiary within the VEA/MRCA claim processes (s 3-4). Any costs of compliance in terms of obtaining records or specialist reports fall on claimants seeking to substantiate the listed factors, or on decision makers who must verify and interpret the evidence against the Statement’s criteria.

This instrument is not a statute that creates new criminal offences or private rights. Instead it is a Statement of Principles made under subsection 196B(2) of the VEA that supplies medical criteria used in the statutory scheme. The key duties and rights therefore arise from how decision‑makers apply this Statement in the VEA/MRCA claim processes.

Duty to apply the Statement in relevant claims: Where a claim falls under section 120A of the VEA or section 338 of the MRCA, the instrument applies (s 4). Administrative decision‑makers assessing whether a reasonable hypothesis exists are expected to consult and apply the factors listed in section 8 and the definitions in Schedule 1 in making that determination. The instrument’s authority is grounded in s 3: it is made under subsection 196B(2) of the VEA and the RMA frames the medical evidence basis in s 7.

Right to have causation assessed against the Statement: A claimant for hypogonadism or death from hypogonadism has the right to have their claim tested against the Statement’s criteria. If at least one of the section 8 factors is established as related to relevant service (see s 9), a reasonable hypothesis is said to be raised. The claimant’s procedural right is therefore to rely upon the Statement as the applicable RMA determination in presenting medical and exposure evidence.

Duty of proof for factors: Although the instrument sets the medical criteria, the claimant bears the practical burden of adducing evidence to show a factor exists. Many factors are defined with measurable thresholds in the Schedule that will require documentary or clinical proof: e.g. BMI history for the five years prior to clinical onset (s 8(33), (71); Schedule 1), cumulative exposure hours for inhaled fumes, chemical agent contact or metal exposures (s 8(28)-(29), (66)-(67)), drug therapy durations and discontinuation/rechallenge evidence (s 8(21)-(27), (59)-(65)), and infection histories with specified organisms (s 8(7)-(9), (45)-(47)). The instrument sets the qualitative and quantitative thresholds; presenting evidence that meets those thresholds is a duty of the claimant if they want the factor accepted.

Duty to relate the factor to relevant service: Section 9 requires that the existence of any factor in section 8 must be related to the person’s relevant service. The instrument does not itself prescribe the method of proving that relationship, but it makes the relationship a necessary element. For subsections 8(39)-(77), section 9(2) further constrains application to material contribution or aggravation where the hypogonadism pre‑existed or was contracted before/during but did not arise out of relevant service.

Interplay with other Statements of Principles: Section 10 imposes a duty on decision‑makers to apply the factors of other Statements of Principles where a cited factor in section 8 refers to an injury or disease that is already covered by another Statement. This creates an obligation to cross‑refer and apply the other Statement’s terms as in force from time to time.

No new private rights or penalties in the Statement: The instrument itself does not create new private entitlements independent of the VEA/MRCA statutory schemes, nor does it create criminal or civil penalties. Its legal force is as an RMA scientific instrument to be used within claims processes. Rights to compensation or rehabilitation remain governed by the VEA or MRCA statutory provisions; the Statement furnishes medical criteria relevant to those determinations (s 3-4, s 7).

The Statement of Principles as compiled contains no express penalty provisions and does not create criminal offences. Its operative role is as a medical criteria instrument under the VEA and MRCA frameworks, rather than as an enforcement instrument that imposes fines, imprisonment or civil sanctions.

Administrative enforcement and decision use: The primary enforcement mechanism is administrative application within the statutory claims process. Decision‑makers charged with applying the VEA and MRCA must consult and apply the RMA’s Statement when determining whether a reasonable hypothesis exists that links hypogonadism (or death from hypogonadism) with relevant service (s 4, s 7). The Statement supplies the factors that must be treated as the medical standard in that assessment. If a decision‑maker accepts that at least one of the factors in section 8 exists and is related to relevant service (per s 9), that finding will influence entitlement decisions under the VEA or MRCA. The instrument does not itself implement entitlement decisions; those will be taken under the relevant statutory provisions.

No criminal or civil penalties in the instrument: Nowhere in the text is there an express penalty provision or sanction for non‑compliance with the Statement itself. The Statement is qualitative and evidentiary. Any penalties that arise in the claims process are governed by the VEA, the MRCA or other applicable laws, not by this Statement.

Enforcement risk and administrative challenge: The practical ‘enforcement’ is a matter of whether claimants can meet the Statement’s thresholds. For many of the listed factors the evidentiary burden is non‑trivial. For example, demonstrating cumulative exposure for 2,000 hours to specified metal fumes or chemical agents requires production of detailed occupational records (s 8(28)-(29)). Requiring documentation, specialist reports and historical records may lead to contested administrative processes and tribunal review if the Department does not accept the evidence. Any disputes will be resolved within the statutory appeal and review mechanisms under the VEA or MRCA; the Statement provides the medical criteria used by those decision‑makers.

Reliance on other Statements: Section 10 requires cross‑application of other Statements of Principles where a factor in s 8 refers to another covered injury or disease. That mechanism affects enforcement in that decision‑makers must also apply the relevant provisions of those other Statements, potentially complicating the administrative assessment by adding parallel or additional criteria.

Amendment and current version: The compilation and endnotes show an amendment history (Endnotes). Decision‑makers must apply the Statement as in force at the relevant time. The Statement itself is maintained as an RMA instrument and may be amended; enforcement in claims will involve applying the Statement current at the time the claim is being assessed under the statutory rules that govern retrospective or transitional application. The instrument does not specify criminal enforcement modalities or civil sanctions.

The instrument is made under subsection 196B(2) of the VEA (s 3) and specifically applies to claims to which section 120A of the VEA or section 338 of the MRCA apply (s 4). It is a component of the broader statutory compensation and rehabilitation regime for veterans and serving members. Its interaction with other laws is therefore primarily functional and evidentiary rather than prescriptive of new legal duties outside that statutory context.

Embedding in the VEA and MRCA claims process: The Statement is designed to be used by decision‑makers determining whether a reasonable hypothesis exists connecting hypogonadism or death from hypogonadism to a person’s relevant service. Sections 3 and 4 establish that the Statement’s role is as an RMA product under the VEA and for claims under the MRCA where relevant. The substantive decision about entitlement, compensation, rehabilitation or treatment remains within the decision‑making framework of the VEA and MRCA. The Statement supplies the medical criteria that feed into those statutory determinations.

Cross‑reference to other Statements of Principles: Section 10 requires that where a factor in section 8 refers to an injury or disease already covered by another Statement of Principles determined under subsection 196B(2) of the VEA, the other Statement’s factors apply in accordance with its terms. This creates a legal mechanism for integrating multiple RMA Statements whenever conditions overlap. For example, a factor that refers to a primary or secondary malignant neoplasm (listed in the specified list of infiltrative diseases in the Schedule) will bring the relevant cancer Statement into play in determining connections to service (s 8(13), Schedule 1, specified list of infiltrative diseases; s 10).

Interaction with clinical and forensic evidence regimes: The Statement defines medical terms and thresholds that will control the medical evidence required in claims. Many of these matters intersect with clinical standards and evidence admissibility in administrative settings. For example, definitions such as chronic kidney disease requiring at least 3 months’ presence (Schedule 1) align with prevailing clinical thresholds and will shape expert opinion and documentary evidence used in administrative determinations. The Statement does not change evidentiary rules per se, but it shapes what counts as the material medical criteria decision‑makers must examine within administrative law processes.

No effect on criminal or workplace law directly: The Statement does not purport to amend criminal law, occupational health and safety obligations, or workers’ compensation law. It is specific to the VEA/MRCA claims environment. However, overlap with workplace exposures, drug usage and occupational injury may cause parallel processes in other regimes (for example industrial compensation claims or employer liability), but the Statement itself contains no provisions that alter those regimes. Where a disease or injury is covered by other Statements, s 10’s cross‑application may create overlap in administrative determinations.

Application timing and transitional questions: The instrument’s endnotes record its registration and amendment history (Endnote 3 and 4). Decision‑makers will need to consider which version of the Statement applies to a particular claim depending on statutory rules about application, saving and transitional provisions for the VEA or MRCA. The compilation notes that uncommenced amendments are not shown and that application, saving and transitional provisions not included in the compilation are noted in endnotes (About this compilation). Practitioners must therefore check the applicable version and any transitional rules when advising clients.

Relationship to clinical practice standards and treatment entitlements: The Statement defines eligibility criteria for a reasonable hypothesis of service connection. Clinical practice standards and medical guidelines remain matters for clinicians and tribunals to consider, but the Statement’s definitions and thresholds will be critical evidence. The instrument does not itself mandate specific clinical care or funding for treatment; entitlement to treatment funding or other benefits is determined under the VEA or MRCA statutory provisions and processes, informed by the Statement.

The compilation includes endnotes that set out the Statement’s legislative history and amendments. The Statement of Principles concerning hypogonadism (Reasonable Hypothesis) (No. 73 of 2021) was registered 24 May 2021 and commenced on 21 June 2021 (Endnote 3). An amendment, Amendment Statement of Principles concerning hypogonadism (Reasonable Hypothesis) (No. 51 of 2022), was registered 2 May 2022 and commenced 30 May 2022 (Endnote 3). The compilation date is 30 May 2022 and includes amendments up to No. 51 of 2022.

Content of amendments recorded in endnotes: Endnote 4 (Amendment history) records how provisions were affected. It shows that Section 2 was affected by a repeal under the Legislation Act s 48D (Endnote 4). The Schedule 1 Dictionary entry for immune checkpoint inhibitor was revised by the 2022 amendment (Endnote 4). The compilation notes that the day of commencement of the amendment was 30 May 2022, and that the compilation includes those changes (Compilation preface).

Compilation and uncommenced amendments: The compilation warns that the effect of uncommenced amendments is not shown in the text and that underlined material in the endnotes indicates uncommenced amendments. Practitioners must check the Legislation Register for any amendments made but not commenced at the compilation date (About this compilation). The compilation also notes that if the operation of a provision or amendment is affected by application, saving or transitional provisions not included in the compilation, those are referenced in the endnotes (About this compilation). This means the version to be applied to a particular claim may be subject to transitional rules which are not printed in the compiled instrument.

Interpretation of amendment entries: The endnotes and the abbreviation key explain how amendments are annotated. For example, “rs” stands for “repaced and substituted” and “(md)” indicates a misdescribed amendment that could be given effect as intended. The endnotes here do not indicate any misdescribed amendments in the entries provided, but practitioners should be alert to such annotations in the full Legislation Register history.

Operational consequence of amendment history: The key operational change recorded in Endnote 4 relates to Schedule 1’s definition of immune checkpoint inhibitor, which was revised in the 2022 amendment. Given that subsection 8(25) and 8(63) refer to taking an immune checkpoint inhibitor within the prior year for clinical onset or worsening, the amendment to the Schedule may alter which agents qualify under those subsections. Decision‑makers and clinicians must therefore use the Schedule as amended when assessing claims from 30 May 2022 onward.

Check for further amendments: The compilation date is 30 May 2022 and it includes amendments up to that date. For any claim assessed after that date, practitioners should confirm whether further amendments have been registered or commenced on the Legislation Register. The compilation itself cautions that changes made after the compilation date are not included.

The compiled instrument contains no references to judicial decisions or tribunal determinations interpreting this particular Statement of Principles. The Statement does not list any cases and the endnotes do not include litigation citations. As a RMA Statement of Principles under subsection 196B(2) of the VEA, disputes about application and interpretation are likely to arise in administrative appeals and possibly in judicial review or merits review under the VEA/MRCA regimes, but no such litigation history is contained in this instrument.

Implication for practitioners: Because this compilation contains no litigation history, practitioners advising on claims must proceed on the text of the Statement and established administrative practice. Where disputes arise about the application of section 8 factors (for example what constitutes sufficient evidence of cumulative exposure hours, or whether a clinical finding meets the Schedule definition), those disputes will be resolved in the statutory decision processes and, if appealed, by the relevant review body or court. Absent precedent-specific guidance from the instrument, advocates should prepare arguments grounded in the text of the Statement and in contemporaneous medical evidence.

Potential future litigation points implicit in the instrument: The Statement contains several features that commonly generate disputes in administrative and tribunal proceedings. Examples include temporal questions such as whether a specified exposure occurred “before the clinical onset” or “within 2 years of cessation” (s 8(28)-(29)); whether drug therapy “cannot be ceased or substituted” (s 8(26), (64)-(66)); interpretation of “inability to obtain appropriate clinical management” (s 8(77)); and the application of the medical thresholds in Schedule 1 such as BMI history or pack‑year calculations. These identifiable issues are the likely loci of future litigation, although the instrument itself does not provide a litigation record.

No cases named in the instrument: The Statement does not cite or rely upon any judicial authorities. Its authority is the RMA’s view of the medical‑scientific evidence (s 7) and its statutory foundation under the VEA. Any case law that develops will be external to the instrument and must be sourced from tribunal and court records, which are not part of this compilation.

This Statement contains multiple technical details and drafting features that create practical risks and pitfalls for claimants and advisers. The following are specific, concrete issues to watch for when preparing or assessing claims.

Sex‑specific provisions and asymmetric thresholds: Many factors in section 8 apply only to males or only to females (e.g. s 8(3), (11), (14), (31), (30), (35)-(36), (38), (52), (68)-(69), (72)-(76)). Practitioners must map each factor carefully to the claimant’s sex and ensure female‑only and male‑only conditions are not asserted in error. Some factors are sex‑specific in unusual ways, for instance certain drugs are listed as sex‑specific in Specified List 2 (Schedule 1).

Exclusions in the hypogonadism definition: The instrument explicitly excludes heritable and congenital forms of hypogonadism, compensated hypogonadism, diminished ovarian reserve, naturally occurring menopause, and abnormal semen analysis (s 6(2)(c)). If a claimant’s presentation fits any of those excluded categories, the Statement will not provide a basis for a reasonable hypothesis. Careful clinical characterisation is required to avoid misclassifying the condition.

Timing language: Many factors require that a condition existed “before the clinical onset of hypogonadism” or “at the time of the clinical onset” or apply to “clinical worsening” (s 8). Establishing the timing of onset or worsening is frequently contentious in claims. Clinical records, specialist notes and objective tests dated contemporaneously are critical. Vague or retrospective descriptions of onset without corroborative records are at risk of being rejected.

Cumulative exposure thresholds and proof burdens: Several exposure factors require cumulative durations, for example 2,000 hours for inhaling fumes from specified metals or chemical agents (s 8(28)-(29)) and 1,000 hours within 10 years for TCDD contamination for females (s 8(30)). Claimants must provide detailed occupational records, rosters, or credible witness statements to meet these thresholds. The instrument also places decay windows on exposures after cessation (e.g. onset within 2 years of cessation for some exposures, 25 years for TCDD‑contaminated agents in females), and these windows can be difficult to demonstrate retrospectively.

Drug therapy complexities: The Schedule separates drugs into Specified List 1 (e.g. alkylating agents, platinum compounds) and Specified List 2 (various agents including androgens, antipsychotics, opioids and sex‑specific items) and imposes different tests and timeframes (Schedule 1; s 8(21)-(27), (59)-(66)). Some provisions require the drug “cannot be ceased or substituted” at the time of clinical onset/worsening (s 8(26), (64)). Establishing that a drug “cannot be ceased or substituted” will likely hinge on specialist opinion and therapeutic necessity, which can be disputed.

Ambiguous or open‑ended factors: Factor 8(77) lists “inability to obtain appropriate clinical management for hypogonadism” as a factor. The instrument does not define what constitutes inability or appropriate management, leaving potential for contest. Claimants asserting this factor should produce contemporaneous evidence of attempts to obtain care, denials, waiting lists or geographical barriers, and expert evidence on what would constitute appropriate management.

Overlap with other Statements and cross‑application: Section 10 cross‑refers to other Statements of Principles. If a factor in section 8 refers to an injury or disease covered by another Statement, the factors in that other Statement apply as in force. Practitioners must identify when an overlap exists (for example malignancy in the infiltrative diseases list) and then check the other Statement for additional criteria or differences in thresholds.

Definition details with surprising conversions: The Schedule’s “one pack‑year” definition equates 1 gram of tobacco to one cigarette, and gives an equivalent of 7,300 grams of smoking tobacco for one pack‑year (Schedule 1). These specific conversions may produce non‑intuitive pack‑year counts for non‑cigarette tobacco use and require careful calculation when smoking history is material (s 8(31), (69)).

Clinical onset versus clinical worsening: The Statement separately lists factors for initial clinical onset and for clinical worsening (e.g. s 8(1)-(38) vs 8(39)-(77)). Subsection 9(2) narrows the application of the second set so that they apply only to material contribution or aggravation where the hypogonadism was suffered or contracted before or during (but not arising out of) relevant service. Misunderstanding this distinction can lead to incorrect arguments about causation versus aggravation.

Definitions that incorporate other technical tests: Chronic kidney disease is defined by abnormality of kidney structure/function present for at least 3 months and uses clinical markers such as GFR < 60 mL/min/1.73 m2, imaging, biopsy, albuminuria or transplant history (Schedule 1). Proof requires nephrology records with the requisite markers documented over time.

Amendment timing: The Schedule’s definition of immune checkpoint inhibitor was revised by Amendment No. 51 of 2022 (Endnote 4). If a claim’s relevant timeframe spans before and after that amendment, advisers must ensure they apply the version in force for the claim in accordance with transitional rules that may exist in the VEA/MRCA regimes.

This section translates the Statement’s requirements into concrete evidence, records and steps that claimants, clinicians and advisers should assemble or take when a claim for hypogonadism or death from hypogonadism is pursued under the VEA or MRCA.

Step 1 , Identify the operative statutory claim: Confirm the claim is within the scope of section 120A of the VEA or section 338 of the MRCA (s 4). This determines that the Statement applies as part of the medical criteria feeding into the entitlement assessment.

Step 2 , Determine the relevant factual issue: Establish whether the claim relies on causation of hypogonadism (clinical onset) or on material contribution/aggravation to pre‑existing hypogonadism (clinical worsening). Use the structure in sections 8 and 9. If the condition pre‑existed or was contracted before or during service, subsections 8(39)-(77) apply only for material contribution/aggravation (s 9(2)).

Step 3 , Map clinical findings to the Statement’s factors: Review the specific factors in section 8 and the Schedule for definitions and numeric thresholds. For example:

• For endocrine diagnoses, obtain laboratory and specialist endocrinology reports showing FSH/LH deficiency or hyperprolactinaemia timed “at the time of the clinical onset” or “at the time of the clinical worsening” as required by s 8(1), (2), (39), (40).

• For surgical or trauma factors, obtain operative reports, surgical discharge summaries and imaging that document excision of ovaries/testes or blunt/penetrating trauma sufficient to cause gonadal atrophy (s 8(4)-(6), (42)-(44)).

• For radiation, obtain radiation oncology records showing the field of radiation included both ovaries/testes or a single functional ovary/testis and the dates of exposure (s 8(6), (44)).

• For infections (HIV, Mycobacterium leprae, Trypanosoma brucei), obtain infectious diseases records and test results with dates preceding clinical onset (s 8(7)-(9), (45)-(47)).

Step 4 , Prove exposure thresholds and durations: For exposures that use cumulative hours (s 8(28)-(30), (66)-(67)), gather employment records, rostering, timesheets, equipment logs, industrial hygiene reports and witness statements that evidence the duration and character of exposure. For TCDD‑contaminated agents in females, collate evidence showing the specified activities (decanting, spraying, handling treated timber, etc.) and calculate cumulative hours within the 10‑year window, including evidence for cessation dates if the onset/worsening occurs after cessation (s 8(30)).

Step 5 , Document drug therapy precisely: For drug‑related factors, obtain pharmacy dispensing records, hospital medication charts and specialist letters that show dates, durations and whether the drug “cannot be ceased or substituted”. For drugs that require discontinuation/rechallenge evidence (s 8(27), (65)), produce documentation of improvement within 2 months of discontinuation or evidence of redevelopment on rechallenge. For Specified List 1 or 2 drugs, check the Schedule’s entries and ensure sex‑specific inclusions are respected (Schedule 1).

Step 6 , Provide lifestyle and biometric histories: For BMI‑related factors, collect longitudinal weight and height records covering at least five years if “being obese” must be shown for five years before onset/worsening (s 8(33), (71); Schedule 1). For smoking, calculate pack‑years using the Schedule’s conversion rules and provide corroborating medical or primary care records (s 8(31), (69); Schedule 1).

Step 7 , Prove timing and service relationship: Establish the temporal relationship between the factor and the person’s relevant service. Section 9 requires that each established factor be related to the person’s relevant service. Provide service records, deployment histories, dates of service episodes and linkages between service events and the identified factor.

Step 8 , Address exclusions and alternative diagnoses: Where the claimant’s presentation might fall within an excluded category under s 6(2)(c) (e.g. naturally occurring menopause, congenital hypogonadism), obtain expert opinion to distinguish the claimant’s clinical picture from the excluded conditions.

Step 9 , Use cross‑referenced Statements where necessary: If a factor refers to a disease covered by another Statement of Principles, obtain and apply that other Statement’s criteria as required by s 10. For example, if the factor involves a primary or secondary malignant neoplasm (Schedule 1, specified list of infiltrative diseases), check the applicable cancer Statement for its factors and evidence demands.

Step 10 , Prepare medico‑legal reports that directly map clinical evidence to the Statement: Have treating clinicians or independent medical examiners produce reports that explicitly address the Statement’s factors and Schedule definitions. Reports should state whether a listed factor exists, the evidence supporting it, its timing relative to clinical onset/worsening, and whether the factor is related to relevant service.

Step 11 , Anticipate and document “inability to obtain appropriate clinical management”: If asserting factor 8(77), compile contemporaneous correspondence showing attempts to access care, referrals declined, waiting lists, geographic barriers, or insurer denials, and include specialist opinions on what constitutes appropriate management in the claimant’s clinical circumstances.

Step 12 , Check applicable version and amendments: Confirm which version of the Statement and Schedule applies to the claim based on the date of assessment and any transitional rules in the VEA/MRCA. The Schedule was amended by No. 51 of 2022 with changes such as the immune checkpoint inhibitor entry (Endnote 4). Ensure reports and submissions use the correct amended definitions.

Step 13 , Prepare for possible review and appeal: Because the Statement sets thresholds that are often factually disputed, prepare record‑level evidence suitable for administrative review or tribunal processes. Anticipate challenges on the sufficiency of evidence,timing, cumulative exposures, drug cessation/rechallenge,and prepare corroborating documentary and expert evidence.

Following these steps aligns claimant evidence with the instrument’s specific factors and definitions. The Statement’s detailed thresholds and sex‑specific rules make precise documentation essential. Practitioners should map evidence item by item to the relevant subsection and Schedule definition, and ensure service records are linked to the factor found to exist.